HSA-C4 NPs effectively inhibit A549cisR tumor growth and metastasis by targeting multiple aspects of TME, including inducing apoptosis through mtDNA damage, reprogramming M2 macrophages to the M1 phenotype, and inhibiting angiogenesis, thereby overcoming cisplatin resistance. Here, C4A is linked to neoplasm.